{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:58:24Z","timestamp":1790920704033,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,8,12]],"date-time":"2012-08-12T00:00:00Z","timestamp":1344729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11523-012-0225-x","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T07:04:26Z","timestamp":1344668666000},"page":"189-195","source":"Crossref","is-referenced-by-count":14,"title":["Inhibition of mTOR in carcinoid tumors"],"prefix":"10.1007","volume":"7","author":[{"given":"Simona","family":"Grozinsky-Glasberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,12]]},"reference":[{"issue":"2","key":"225_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","volume":"31","author":"IM Modlin","year":"2010","unstructured":"Modlin IM, Pavel M, Kidd M, Gustafsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31(2):169\u2013188","journal-title":"Aliment Pharmacol Ther"},{"issue":"28","key":"225_CR2","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656\u20134663","journal-title":"J Clin Oncol"},{"issue":"2","key":"225_CR3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2):157\u2013176","journal-title":"Neuroendocrinology"},{"issue":"1","key":"225_CR4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","volume":"87","author":"B Eriksson","year":"2008","unstructured":"Eriksson B, Kloppel G, Krenning E et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors\u2014well-differentiated jejunal-ileal tumor\/carcinoma. Neuroendocrinology 87(1):8\u201319","journal-title":"Neuroendocrinology"},{"key":"225_CR5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/1471-2407-9-388","volume":"9","author":"MP Brizzi","year":"2009","unstructured":"Brizzi MP, Berruti A, Ferrero A et al (2009) Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network. BMC Cancer 9:388","journal-title":"BMC Cancer"},{"issue":"1","key":"225_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000225389","volume":"90","author":"F Maire","year":"2009","unstructured":"Maire F, Hammel P, Faivre S et al (2009) Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology 90(1):67\u201372","journal-title":"Neuroendocrinology"},{"issue":"5","key":"225_CR7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","volume":"59","author":"E Bajetta","year":"2007","unstructured":"Bajetta E, Catena L, Procopio G et al (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59(5):637\u2013642","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"225_CR8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ceb.2005.02.010","volume":"17","author":"JR Woodgett","year":"2005","unstructured":"Woodgett JR (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17(2):150\u2013157","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"225_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","volume":"4","author":"J Luo","year":"2003","unstructured":"Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4(4):257\u2013262","journal-title":"Cancer Cell"},{"issue":"1","key":"225_CR10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12(1):9\u201322","journal-title":"Cancer Cell"},{"issue":"4","key":"225_CR11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1471-4892(03)00071-7","volume":"3","author":"S Huang","year":"2003","unstructured":"Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3(4):371\u2013377","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"225_CR12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5):335\u2013348","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"225_CR13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671\u2013688","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"225_CR14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pbc.21296","volume":"50","author":"PJ Houghton","year":"2008","unstructured":"Houghton PJ, Morton CL, Kolb EA et al (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(4):799\u2013805","journal-title":"Pediatr Blood Cancer"},{"issue":"9637","key":"225_CR15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456","journal-title":"Lancet"},{"issue":"1","key":"225_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jjco\/hyp120","volume":"40","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Doi T, Ohtsu A et al (2010) Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40(1):17\u201323","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"225_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28(1):69\u201376","journal-title":"J Clin Oncol"},{"issue":"11","key":"225_CR18","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","volume":"13","author":"RT Abraham","year":"2007","unstructured":"Abraham RT, Gibbons JJ (2007) The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13(11):3109\u20133114","journal-title":"Clin Cancer Res"},{"issue":"50","key":"225_CR19","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50):7455\u20137464","journal-title":"Oncogene"},{"issue":"2","key":"225_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00022744-200206000-00008","volume":"10","author":"L Wang","year":"2002","unstructured":"Wang L, Ignat A, Axiotis CA (2002) Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 10(2):139\u2013146","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"225_CR21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100057","volume":"85","author":"K Zitzmann","year":"2007","unstructured":"Zitzmann K, De Toni EN, Brand S et al (2007) The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85(1):54\u201360","journal-title":"Neuroendocrinology"},{"issue":"3","key":"225_CR22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000111501","volume":"87","author":"S Grozinsky-Glasberg","year":"2008","unstructured":"Grozinsky-Glasberg S, Franchi G, Teng M et al (2008) Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology 87(3):168\u2013181","journal-title":"Neuroendocrinology"},{"issue":"18","key":"225_CR23","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1002\/cncr.26011","volume":"117","author":"B Svejda","year":"2011","unstructured":"Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM (2011) Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1\/2 and AKT. Cancer 117(18):4141\u20134154","journal-title":"Cancer"},{"issue":"9","key":"225_CR24","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","volume":"95","author":"I Duran","year":"2006","unstructured":"Duran I, Kortmansky J, Singh D et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9):1148\u20131154, Epub 2006 Oct 10","journal-title":"Br J Cancer"},{"issue":"6","key":"225_CR25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514\u2013523","journal-title":"N Engl J Med"},{"issue":"26","key":"225_CR26","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26(26):4311\u20134318","journal-title":"J Clin Oncol"},{"issue":"9808","key":"225_CR27","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005\u20132012","journal-title":"Lancet"},{"key":"225_CR28","doi-asserted-by":"crossref","unstructured":"Yao J, Hainsworth JD, Wolin EM et al (2012) Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). J Clin Oncol 30 (suppl 4; abstr 157)","DOI":"10.1200\/jco.2012.30.4_suppl.157"},{"key":"225_CR29","doi-asserted-by":"crossref","unstructured":"Pavel M, Wiedenmann B, Capdevila J, Reed N, Valle JW, Caglio S, May C, Comis S, Castellana R, de Herder WW, Metzner C, Salazar R, H\u00f6rsch D, \u00d6berg K (2012) RAMSETE: a single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuroendocrine tumours in Europe. J Clin Oncol 30 (suppl; abstr 4122)","DOI":"10.1200\/jco.2012.30.15_suppl.4122"},{"issue":"10","key":"225_CR30","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","volume":"28","author":"D Bushnell","year":"2010","unstructured":"Bushnell D, O'Dorisio TM, O'Dorisio MS et al (2010) 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28(10):1652\u20131659","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-012-0225-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-012-0225-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-012-0225-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T10:05:46Z","timestamp":1714298746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-012-0225-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1007\/s11523-012-0225-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,12]]}}}